Adrianne Parkey
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Graduate Student Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Adrianne Parkey's research focuses on pediatric health conditions, with recent publications examining treatment outcomes and rare case presentations. Her work includes an investigation into the efficacy of first-line rituximab for pediatric-onset multiple sclerosis, analyzing both clinical and MRI data from a retrospective cohort. Additionally, she has contributed to a case report detailing reversible pulmonary arterial hypertension in a young child caused by fenfluramine use. Parkey collaborates with researchers at the University of Arkansas for Medical Sciences, including Debopam Samanta, Raghu Ramakrishnaiah, Praveen Kumar Ramani, and Hannah Lewis, with whom she shares one publication.
Metrics
- Publications: 2
Selected Publications
-
First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort (2026)
-
Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report (2026)
Collaboration Network
Top Collaborators
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
Similar Researchers
Based on overlapping research topics